Deficiency of late complement components in patients with severe and recurrent meningococcal infections. 1996

R Cremer, and V Wahn

UI MeSH Term Description Entries
D008297 Male Males
D008589 Meningococcal Infections Infections with bacteria of the species NEISSERIA MENINGITIDIS. Meningococcal Septicemia,Infections, Meningococcal,Meningococcal Disease,Infection, Meningococcal,Meningococcal Diseases,Meningococcal Infection,Septicemia, Meningococcal
D011414 Properdin A 53-kDa protein that is a positive regulator of the alternate pathway of complement activation (COMPLEMENT ACTIVATION PATHWAY, ALTERNATIVE). It stabilizes the ALTERNATIVE PATHWAY C3 CONVERTASE (C3bBb) and protects it from rapid inactivation, thus facilitating the cascade of COMPLEMENT ACTIVATION and the formation of MEMBRANE ATTACK COMPLEX. Individuals with mutation in the PFC gene exhibit properdin deficiency and have a high susceptibility to infections. Complement Factor P,Factor P, Complement
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D003165 Complement System Proteins Serum glycoproteins participating in the host defense mechanism of COMPLEMENT ACTIVATION that creates the COMPLEMENT MEMBRANE ATTACK COMPLEX. Included are glycoproteins in the various pathways of complement activation (CLASSICAL COMPLEMENT PATHWAY; ALTERNATIVE COMPLEMENT PATHWAY; and LECTIN COMPLEMENT PATHWAY). Complement Proteins,Complement,Complement Protein,Hemolytic Complement,Complement, Hemolytic,Protein, Complement,Proteins, Complement,Proteins, Complement System
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001428 Bacterial Vaccines Suspensions of attenuated or killed bacteria administered for the prevention or treatment of infectious bacterial disease. Bacterial Vaccine,Bacterin,Vaccine, Bacterial,Vaccines, Bacterial
D022401 Meningococcal Vaccines Vaccines or candidate vaccines used to prevent infection with NEISSERIA MENINGITIDIS. Bivalent Meningococcal Vaccine,Menactra,Meningococcal Polysaccharide Vaccine,Meningococcal Vaccine,Menomune,Menveo,Tetravalent Meningococcal Vaccine,Meningococcal Vaccine, Bivalent,Meningococcal Vaccine, Tetravalent,Polysaccharide Vaccine, Meningococcal,Vaccine, Meningococcal,Vaccine, Meningococcal Polysaccharide,Vaccines, Meningococcal

Related Publications

R Cremer, and V Wahn
August 1983, The Journal of infectious diseases,
R Cremer, and V Wahn
February 1993, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology,
R Cremer, and V Wahn
May 1991, The Journal of infection,
R Cremer, and V Wahn
January 1993, Acta clinica Belgica,
Copied contents to your clipboard!